Skip to content
Citation only via Europe PMC

Angiotensin II-induced hypertension does not exacerbate α-SYNUCLEIN pathology in a mouse model of Parkinson's disease.

Silva-Llanes I, Flores-Téllez D, Arrua WJ, El Jouhari NB, Oliver E, Martínez A, Briones AM, Lastres-Becker I.

Frontiers in immunology · 2026

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of nigrostriatal dopaminergic neurons accompanied by chronic neuroinflammation and α-SYNUCLEIN (α-SYN) aggregation. Increasing evidence suggests that cardiovascular comorbidities, including arterial hypertension, may contribute to neurodegenerative processes through vascular dysfunction and sustained inflammatory signaling. However, whether hypertension directly exacerbates α-SYN-induced neurodegeneration and inflammasome activation remains unclear. Here, we investigated the impact of chronic Angiotensin II (AngII)-induced hypertension in an adeno-associated viral vector (AAV)-based mouse model of PD driven by unilateral overexpression of human α-SYN in the <i>Substantia Nigra</i> (SN). Chronic AngII infusion produced a robust hypertensive phenotype but did not aggravate α-SYN-induced loss of tyrosine hydroxylase-positive dopaminergic neurons. Similarly, hypertension failed to modify α-SYN-driven astrogliosis, microgliosis, or microglial morphological activation. Molecular analyses revealed that α-SYN overexpression markedly increased the expression of inflammatory mediators and pyroptosis-related genes, including <i>Nlrp3</i>, <i>Asc</i>, <i>Casp1</i>, <i>Il1b</i>, <i>Il18rap</i>, and <i>Gsdmd</i>. Nevertheless, hypertension did not potentiate these responses. Immunofluorescence analyses further demonstrated that GSDMD expression was predominantly localized in IBA1-positive microglial cells and was significantly elevated following α-SYN overexpression independently of hypertensive status. Collectively, these findings indicate that chronic AngII-induced hypertension is insufficient to exacerbate early α-SYN-mediated neurodegeneration, gliosis, or inflammasome-associated pyroptotic pathways in the SN. Our study suggests that α-SYN pathology itself constitutes the dominant driver of neuroinflammatory activation in this experimental paradigm and that additional vascular or aging-related mechanisms may be required for hypertension to significantly influence PD progression.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.3389/fimmu.2026.1894579
Canonical
link ↗
Fetched
2026-10-20 MST

Cite this

APA
I, S., D, F., WJ, A., NB, E.J., E, O., A, M., AM, B., &amp; I., L. (2026). Angiotensin II-induced hypertension does not exacerbate α-SYNUCLEIN pathology in a mouse model of Parkinson's disease. <em>Frontiers in immunology</em>. https://doi.org/10.3389/fimmu.2026.1894579
Vancouver
I S, D F, WJ A, NB EJ, E O, A M, et al. Angiotensin II-induced hypertension does not exacerbate α-SYNUCLEIN pathology in a mouse model of Parkinson's disease. Frontiers in immunology. 2026. doi:10.3389/fimmu.2026.1894579.
BibTeX
@article{silvallanes2026Angiot, title = {Angiotensin II-induced hypertension does not exacerbate α-SYNUCLEIN pathology in a mouse model of Parkinson's disease.}, author = {Silva-Llanes I and Flores-Téllez D and Arrua WJ and El Jouhari NB and Oliver E and Martínez A and Briones AM and Lastres-Becker I.}, journal = {Frontiers in immunology}, year = {2026}, doi = {10.3389/fimmu.2026.1894579}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings